PharmaNet Development Group, Inc. Expert Shares Strategies for Clinical Development of Biosimilars at Upcoming Conference in China
On Tuesday June 1, Dr. Jeffrey Freitag, Senior Vice President, PharmaNet Consulting, will share his expertise in a presentation entitled "Clinical Development Strategies for Biosimilars." Drawing from his experience of more than twenty years in the pharmaceutical industry, Dr. Freitag will discuss many aspects of biosimilar development including determining budgets and timelines in clinical development, considerations to ensure compliance with regulatory requirements, issues around drug safety management and pharmacovigilance and the key challenges and strategies for monoclonal antibody biosimilars. This is one of several presentations that PharmaNet professionals are making at international meetings dealing with biosimilar drug development.
Dr. Freitag heads a team of experienced pharmaceutical consultants, many of whom are former officials of the FDA or other regulatory agencies, who provide strategic clinical development consultation to clients in a variety of therapeutic areas. He is board certified in both Internal Medicine and Nephrology and has extensive experience in providing medical and scientific direction and leadership to product development teams.
About PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees in 34 countries and more than 42 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.
Contact: Anne-Marie Hess
Phone: (609) 951-6842
SOURCE PharmaNet Development Group, Inc.